文献速递前列腺增生与排尿功能障碍

药物治疗与微创治疗作为中重度良性前列腺增生初始治疗的成本效果研究

Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-06-10

该模型为基础的经济学评价模拟了平均年龄65岁、平均国际前列腺症状评分16.6的男性良性前列腺增生患者终生疾病进展,从美国公共支付方角度估算每质量调整生命年的医疗成本,并逐年贴现3%。结果显示,初始水蒸气热疗(WVTT)产生的质量调整生命年最高(13.05)且成本最低(15461美元),在成本效用分析中优于其他三种策略。作者认为WVTT是一种有效且节省成本的程序,可能成为寻求更快改善且不终身每日服药的中重度良性前列腺增生患者药物治疗的适当一线替代方案。

要点

  • 初始WVTT产生最高QALYs(13.05)和最低成本(15461美元)。
  • WVTT作为初始治疗在成本效用分析中优于其他三种策略。
  • 作者认为WVTT可能成为中重度BPH患者药物治疗的适当一线替代方案。

核心结论

  • WVTT是一种有效且节省成本的程序,可能成为寻求更快改善且不终身每日服药的中重度良性前列腺增生患者药物治疗的适当一线替代方案。

研究设计与样本

  • 本研究为模型为基础的经济学评价,模拟平均年龄65岁、平均国际前列腺症状评分16.6的男性良性前列腺增生患者终生疾病进展。
  • 从美国公共支付方角度估算每质量调整生命年的医疗成本,并逐年贴现3%。
  • 模型中男性可接受最多三线治疗:初始药物治疗后以微创治疗为二线、经尿道前列腺电切术或药物治疗为三线;或初始微创治疗(WVTT或PUL)后以微创治疗再次、经尿道前列腺电切术或药物治疗为二线、经尿道前列腺电切术为三线。
  • 模型数据来自已发表文献,并进行了概率分析。

主要发现

  • 初始WVTT治疗产生的QALYs最高(13.05)且成本最低(15461美元)。
  • 药物治疗后序贯WVTT的累积QALYs为12.92、终生成本为20280美元。
  • 药物治疗后序贯PUL的累积QALYs为12.87、终生成本为22424美元。
  • 初始PUL治疗的累积QALYs为12.86、终生成本为20930美元。
  • 在成本效用分析中,WVTT作为初始治疗优于所有三种策略,即以更低成本产生更多QALYs。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recently, minimally invasive therapies (MITs), such as water vapor thermal therapy (WVTT) and prostatic urethral lift (PUL) have become an alternative to surgery or pharmacotherapy to manage benign prostatic hyperplasia (BPH), offering symptom relief with a favorable safety profile. The objective of this study was to evaluate the cost-utility of MITs (WVTT and PUL) compared to pharmacotherapy as initial treatment for patients with moderate-to-severe BPH. METHODS: In this model-based economic evaluation we simulated BPH progression in men (mean age 65 years, average International Prostate Symptom Score 16.6) over their lifetime and estimated healthcare costs (from the US public payer perspective) per quality-adjusted life year (QALY), discounted at 3% annually. Various clinical scenarios were evaluated given that most men undergo several lifelong therapies up to surgical intervention and potentially thereafter. As such, in the study model men could receive up to three lines of therapy: (1) initial pharmacotherapy with MIT as second-line, and transurethral resection of the prostate (TURP) or pharmacotherapy as third-line; (2) initial MIT (WVTT or PUL) with MIT again, TURP or pharmacotherapy as second-line, and TURP as third-line. Model was populated using data from the published literature. Probabilistic analyses were performed. RESULTS: Initial treatment with WVTT led to the highest QALYs (13.05) and the lowest cost ($15,461). The cumulative QALYs and lifetime costs were 12.92 QALYs and $20,280 for pharmacotherapy followed by WVTT, 12.87 QALYs and $22,424 for pharmacotherapy followed by PUL, 12.86 QALYs and $20,930 for initial treatment with PUL. In the cost-utility analysis, WVTT as initial treatment dominated all three strategies, i.e., generated more QALYs at a lower cost. CONCLUSION: WVTT is an effective and cost-saving procedure, and may be an appropriate first-line alternative to pharmacotherapy for moderate-to-severe BPH patients who seek faster improvement and no lifelong commitment to daily medications.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Sahakyan Y, Erman A, Bhojani N, et al. Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study. Prostate Cancer Prostatic Dis. 2022. PMID: 35689083. doi:10.1038/s41391-022-00561-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。